# A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Study · id `cardio:ct-nct02331680` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02331680](<https://clinicaltrials.gov/study/NCT02331680>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02331680

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

## Technical summary

Registry record NCT02331680. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2019-10-22.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 124 participants (enrolled count; ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Primary completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Results first posted: 2019-10-22 (ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02331680, source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02331680-2019-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- Condition: Chronic Renal Failure
- Intervention (Drug): OPC-41061
- Intervention (Drug): OPC-41061
- Intervention (Drug): Placebo
- Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Otsuka Pharmaceutical Co., Ltd. (`cardio:org-otsuka-pharmaceutical-co-ltd`)

## Provenance

Content hash: 1d1cf88b18dc5bdf92f8c862686398aca46eafd8bd442432f96881edfd1d6a8f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
